Navigation Links
ViroPharma to Present at Three November Healthcare Conferences
Date:10/29/2009

EXTON, Pa., Oct. 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company will be presenting at several upcoming healthcare investment conferences.

Vincent Milano, president and chief executive officer of ViroPharma, will present at the Oppenheimer 20th Annual Healthcare Conference at 4:30 P.M. EST on Tuesday, November 3, 2009. The conference is being held at the Waldorf=Astoria in New York City.

Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Credit Suisse 2009 Healthcare Conference at 12:00 P.M. MST on Wednesday, November 11, 2009. The conference is being held at the Arizona Biltmore Hotel in Phoenix, AZ.

William Roberts, vice president, corporate communications will present at the Lazard Capital Markets 6th Annual Healthcare Conference at 2:45 P.M. EST on Wednesday, November 18, 2009. The conference is being held at the St. Regis Hotel in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma to Present at Four Additional Healthcare Conferences
2. ViroPharma to Present at Several Upcoming Healthcare Conferences
3. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
4. ViroPharma to Present at Two June Healthcare Conferences
5. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
6. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
7. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
8. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
10. ViroPharma to Present at Three November Healthcare Conferences
11. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , Jan. 23, 2017 /PRNewswire/ - Resverlogix Corp. ... results from the New Zealand ... patients. The data showed remarkable results in reducing inflamed ... healthy control patients. It is believed that this is ... connection of this type can be made between epigenetic ...
(Date:1/23/2017)... PA (PRWEB) , ... January 23, 2017 , ... ... Thomas has been appointed Vice President, Preclinical Safety and Senior Director, Safety Pharmacology. ... of Madras in India. , Dr. Thomas’ career as an academic and ...
(Date:1/23/2017)... ... January 23, 2017 , ... AxioMed will be ... (CANS) annual meeting in Montego Bay, Jamaica from January 26-28th. “We’re excited to ... for surgeons to experience the simplicity of the surgical technique,” said Jake Lubinski, ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L Scientific Inc, a ... ( http://www.gandlscientific.com ), has announced the opening of new offices in Cambridge, Massachusetts, ... and contractors. This is the latest step in G&L’s expansion of its global ...
Breaking Biology Technology:
(Date:12/15/2016)... ... and Markets has announced the addition of the "Global Military Biometrics ... forecasts the global military biometrics market to grow at a CAGR of ... prepared based on an in-depth market analysis with inputs from industry experts. ... coming years. The report also includes a discussion of the key vendors ...
(Date:12/15/2016)... Dec. 15, 2016  There is much more to ... starting the engine. Continental will demonstrate the intelligence of ... Vegas . Through the combination of the keyless ... and biometric elements, the international technology company is opening ... and authentication. "The integration of biometric elements ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at Trinity ... for graphene by combining the material with Silly ... sensitive pressure detector able to sense pulse, blood ... small spider.  The research team,s ... be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):